Cardiogen

Cardiogen (Ala-Glu-Asp-Arg / AEDR) is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It targets cardiac tissue through modulation of fibroblast proliferation, suppression of cardiomyocyte apoptosis via p53 downregulation, and upregulation of cytoskeletal and nuclear matrix proteins. Preclinical research has explored its potential in cardiac remodeling, myocardial injury recovery, and age-related cardiovascular decline. All published studies to date are based on in vitro experiments and animal models.

• Cardiac Tissue Support
• Post-Injury Remodeling
• Chronic Heart Conditions

Direct systemic delivery for cardiac tissue support, established reconstitution protocols, most commonly studied administration route in preclinical research

Subcutaneous injection provides systemic distribution allowing AEDR tetrapeptide to reach cardiac tissue and modulate fibroblast proliferation and cardiomyocyte apoptosis pathways

Research protocols from published literature — not dosing recommendations.

• BPC-157 — Synergistic: Theoretical synergy based on complementary mechanisms - Cardiogen supports cardiac tissue while BPC-157 promotes healing in gut and soft tissues. No published combination studies exist.
• TB-500 — Synergistic: Theoretical synergy based on complementary mechanisms - TB-500 promotes blood vessel formation and broad tissue repair while Cardiogen provides heart-specific support. No published combination studies exist.
• Pinealon — Compatible: Complementary Khavinson bioregulators targeting different organ systems. Pinealon supports neuroprotection while Cardiogen targets cardiac tissue. Routinely combined in Russian longevity protocols.
• Cartalax — Compatible: Fellow Khavinson bioregulator targeting cartilage and connective tissue. Different tissue specificity allows combination without overlap. Used together in comprehensive anti-aging protocols.
• Thymosin Alpha-1 — Compatible: Thymosin Alpha-1 supports immune modulation while Cardiogen targets cardiac tissue. Different mechanisms with no known interactions. May complement each other in recovery protocols.
• Epitalon — Synergistic: Theoretical synergy through complementary pathways. Epitalon activates telomerase and regulates pineal function while Cardiogen supports cardiac tissue maintenance. Combined in Russian geroprotective protocols but no published combination studies exist.
• Conventional Cardiovascular Medications — Monitor Combination: Russian clinical practice uses Cardiogen alongside conventional treatments for heart conditions. Monitor cardiovascular parameters when combining with existing cardiac medications.
• Growth Factors (IGF-1, HGH) — Monitor Combination: Both affect tissue proliferation pathways. Monitor for excessive fibroblast activation or unexpected tissue changes when combining growth-promoting compounds.

Supplies:

• Bacteriostatic water (BAC water)
• Insulin syringes (29-31 gauge)
• Alcohol swabs
• Cardiogen lyophilized powder vial

1. 1Allow vial to reach room temperature (15-20 minutes)
2. 2Clean vial top with alcohol swab and allow to dry
3. 3Calculate required bacteriostatic water volume using the calculator below
4. 4Draw calculated volume of bacteriostatic water into syringe
5. 5Inject water slowly down the inside wall of the vial (never directly onto powder)
6. 6Gently swirl until powder completely dissolves (never shake)
7. 7Solution should be clear - discard if cloudy or contains particles
8. 8Store reconstituted solution in refrigerator at 2-8°C, protected from light

Week 1-2: No significant observable changes expected. Week 2-4: Preclinical research suggests cellular-level effects on cardiac tissue. Long-term: Benefits are theoretical based on animal and in vitro data only. Side effects: Minimal injection site reactions reported. No human clinical trials have established efficacy timelines.

Not approved for human use by any regulatory agency. All published research is preclinical (animal and in vitro studies). Use sterile injection technique and rotate injection sites. Store reconstituted peptide in refrigerator, protected from light. Not recommended during active cancer due to proliferative effects on fibroblasts. Contraindicated in pregnancy and lactation due to absence of safety data. Medical supervision recommended.

Not approved for human use by any regulatory agency. All published research is preclinical (animal and in vitro studies). Use sterile injection technique and rotate injection sites. Store reconstituted peptide in refrigerator, protected from light. Not recommended during active cancer due to proliferative effects on fibroblasts. Contraindicated in pregnancy and lactation due to absence of safety data. Medical supervision recommended.

Cardiogen should be stored at Refrigerate at 2-8°C, use within 30 days after reconstitution.